Holen Sie sich die Stockscreener-App
14.52
10.81%
-1.76
Telix Pharmaceuticals Ltd Adr Aktie (TLX) Neueste Nachrichten
Telix Pharma slides 10% on SEC probe into cancer treatment - Investing.com
Telix Earnings Report: $204M Revenue Crushes Estimates as New Drug Launch Boosts Growth - Stock Titan
Medicare Grants Crucial Reimbursement Code for Telix's Next-Gen Prostate Cancer Imaging Agent - Stock Titan
FDA Approval: Illuccix Expansion Could Add 20,000 Annual Prostate Cancer Scans - Stock Titan
Revolutionary Dual-Isotope Cancer Imaging: Telix Unveils AlFluor Platform with Phase 3 Trial Success - Stock Titan
Revolutionary PSMA-PET Imaging Agent Gozellix Transforms Prostate Cancer Detection Across United States - Stock Titan
Leading Cancer Experts Reveal Future of Radiopharmaceuticals at Telix NYC Investor Day - Stock Titan
5 of the best ASX 200 shares to buy in June - The Motley Fool Australia
Telix Leaders Reveal Next-Gen Radiopharmaceutical Pipeline at Exclusive NYC Investor Day - Stock Titan
Radiopharmaceuticals Market Products and Applications Report 2025 | SPECT Radiopharmaceuticals Lead Diagnostic Market with 67% Share - GlobeNewswire Inc.
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy - Stock Titan
Major Breakthrough: France Grants Approval for Advanced Prostate Cancer Detection Technology - Stock Titan
Telix Delivers Record $186M Q1 Revenue as New FDA-Approved Cancer Imaging Agent Bolsters Portfolio - Stock Titan
Breakthrough Brain Cancer Treatment Doubles Survival Time: Phase 2 Results Revealed - Stock Titan
Telix's Groundbreaking Prostate Cancer Imaging Tech Secures Nationwide Distribution Network - Stock Titan
Telix Pharmaceuticals appoints new CTO - Investing.com
Major Board Addition: Ex-GSK and Sanofi Leader Joins Telix Pharmaceuticals - Stock Titan
Revolutionary Cancer Diagnostic Begins Human Trials: First Patient Receives Novel Sarcoma Imaging Agent - Stock Titan
FDA Green Lights Revolutionary Prostate Cancer Detection Tool: What Makes Gozellix a Game-Changer - StockTitan
Telix Pharmaceuticals Limited (ASX:TLX) Receives FDA Approval for Gozellix® - The Capital Club
Paladin Energy Ltd (ASX:PDN) Suspends Operations at Langer Heinrich Mine - The Capital Club
Major Breakthrough: First PSMA-PET Imaging Agent Approved in Brazil's $330M Market - StockTitan
Telix's Game-Changing Isotope Technology Revolutionizes Cancer Treatment Production - StockTitan
Can Telix's Cancer Therapies Transform Urology Treatment? Top Oncologists Weigh In - StockTitan
Could This New Kidney Cancer Imaging Tool Transform Diagnosis? FDA Fast-Tracks Review - StockTitan
Could This New Prostate Cancer Treatment Change Patient Outcomes? Miami Trial Now Recruiting - StockTitan
〈強茂展望〉擴大海外布局 越南廠最快2026年量產 - Yahoo 財經
Telix Pharmaceuticals Ltd (TLPPF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Can Telix's Triple Product Launch in 2025 Justify Its Bold $1.2B Revenue Target? - StockTitan
特朗普：或將DOGE所節省開支的20%歸還予美國納稅人 - Yahoo 財經
港股美國預託證券與本港收市比較個別發展 - Yahoo 財經
據報匯控最快下周啟動投行部門新一輪裁員 由亞洲開始 - Yahoo 財經
Clinical Trial Success: Telix's Revolutionary Prostate Cancer Treatment Shows Promising Results - StockTitan
Major Breakthrough: Revolutionary Prostate Cancer Detection Tool Gets UK Green Light - StockTitan
分析國產人工智能 DeepSeek 的優與劣及其競爭力 - Yahoo 財經
Telix Pharmaceuticals acquires ImaginAb assets and technology - Investing.com
Telix Pharmaceuticals Acquires RLS USA in Major $230M Radiopharmacy Network Deal - Stock Titan
ImaginAb Sells Therapeutic Pipeline to Telix Pharmaceuticals, Focuses on CD8 ImmunoPET Development - Stock Titan
Telix Pharmaceuticals Secures European Approval for Breakthrough Prostate Cancer Imaging Agent Illuccix - Stock Titan
Telix Pharmaceuticals Hits Record $517M Revenue, Up 55% as Cancer Imaging Portfolio Expands - Stock Titan
Telix Pharmaceuticals Acquires ImaginAb's Cancer Drug Pipeline in $45M Strategic Deal - StockTitan
ASX December health sector winners… and a 91pc drop for a trial-flopped stock - Stockhead
勞力士據報因材料及勞動力成本上漲 加價最多8% - Yahoo 財經
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
無人機技術公司Red Cat(RCAT.US)股價漲18% 將與Palantir(PLTR.US)合作 - Yahoo 財經
Clayton Utz M&A partner Niro Ananda set to resign; KWM eyed - The Australian Financial Review
Health Check: ASX sleep company emerges from slumber with a revenue and earnings upgrade - Stockhead
〈熱門股〉正崴切入BBU 股價直奔漲停創4個月高 - Yahoo 財經
UBS bullish on Telix stock—Illuccix growth & therapeutic expansion fuel upside - Investing.com
Key Investors Say Bet on These Stocks at Sohn Australia Conference - BNN Bloomberg
TLXTelix Pharmaceuticals Ltd ADR Latest Stock News & Market Updates - Stock Titan
Telix Pharmaceuticals Debuts on Nasdaq Global Select Market Under TLX Symbol - Stock Titan
本港首宗De-SPAC完成交割 匯德收購名稱今起變更為獅騰控股 - Yahoo 財經
Guess which top 100 ASX stock is venturing off to the Nasdaq - The Motley Fool Australia
Telix Files Form 20-F Registration Statement for Nasdaq ADS - Yahoo Finance
迪生創建(00113)及潘廸生獲證監會通知就市場失當行為展開研訊 - Yahoo 財經
紫金礦業：擬10億美元收購紐蒙特子公司 - Yahoo 財經
珩灣科技(01523)委任趙芷盈為執行董事 - Yahoo 財經
朸濬國際(01355.HK)控股股東抵押2.69億股普通股及2,750萬元應收帳款 - Yahoo 財經
Up 66% in FY24, will Telix Pharmaceuticals shares continue? - The Motley Fool Australia
4.56%
0.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):